biomed devic servic
price close busi june
domin global leader next
gener sequenc instrument
growth vector point right
takeaway road buy rais pt
recent privileg host illumina cfo ad vice-president investor
relat jacqui ross investor meet manag emphas earli
number growth vector sequenc stress investor apprehens
instrument biggest misunderstood aspect stock seem get
good news custom least monthli given rise confid multi-
year sustain doubl digit top bottom line growth rais estim
take pt street-high pt buy
razorblad believ investor need stop fret instrument
revenu rev focu growth sequenc servic rev
expect grow double-digit year state obviou faster
grow bigger get less import instrument becom instrument
rev two year ago model
instrument consumables/servic
pictur huge market think penetr estim peopl
ever sequenc develop world popul estim
genotyp world develop popul estim
cancer patient babi rare diseas sequenc
respect cost whole genom sequenc wg drop
person lower today expect within year see
path peopl sequenc next year driven
pop seq liquid biopsi studi cancer children
think sequenc project given lead accuraci
throughput cost note we could add million count
consum genotyp to-dat envis year
updat sinc analyst day
ad nipt carrier screen rare undiagnos diseas babi
consum genom oncolog pop seq
estim revis least develop world alon
think demand elast big wait get
genom base convers larg custom indic
good sens demand sequenc look like cost
sequenc drop increment wouldnt
quantifi inflect look like
pop seq liquid biopsi studi drive multi-year demand count peopl
sequenc within next year popul sequenc liquid biopsi
studi pop seq uk lead fast-follow includ us china franc
among pop seq project underway see figur estim least
peopl sequenc grail alon within year
surpris us includ geising offer whole exom sequenc
member radi children demonstr util screen babi
uk lead govern across world step want feel
left behind popul sequenc genotyp stori
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
growth vector point
right takeaway road
remain top pick buy rais pt
recent privileg host illumina cfo ad vice-president investor
relat jacqui ross investor meet toronto manag emphas
earli number growth vector sequenc stress investor
apprehens instrument biggest misunderstood aspect stock
seem get good news custom least monthli basi given
rise confid multi-year sustain double-digit top- bottom-lin
growth rais estim take price target street-high
reiter buy rate pt use premium multipl adj
ep estim adj ep estim
rais estim result increas confid
rise demand popul sequenc liquid biopsi studi consum
genom name three rais revenu ep
estim rais rev y/i
rais adj ep
rais revenu y/i prior
rais adj ep increas
genotyp servic bucket relax
conserv assumpt bake estim instrument revenu
slightli rais novaseq pull-through estim
per system rais estim
per system model total instrument
revenu y/i prior estim rais
instrument rev y/i prior estim
differ novaseq ilmn hiseq shorter life
cycl year initi estim believ life cycl
novaseq year longer requir purchas
unit novaseq consum less expens averag
compar hiseq custom novaseq unlock new test
exom liquid biopsi single-cel rna-seq nascent market well
known believ biggest limit price tag
million capit exchang ultra-high throughput sequenc fewer
institut global requir much power
razorblad believ investor need stop fret instrument
revenu ilmn rev focu growth sequenc
servic rev expect grow double-digit year state
obviou faster grow bigger get less relev instrument
becom instrument rev two year ago
model instrument consumables/servic
illustr robust demand remind drove overal
revenu growth driven q/q array services/oth record
primarili due process ancestri com sampl order
holiday season microarray consum also record y/i
q/q primarili direct-to-consum industri leader dtc
custom agrigenom drove y/i growth services/oth
y/i growth consum driven robust sequenc wg we
liquid biopsi guid revenu modestli q/q
buy unchang target price june
biomed devic servic
driven on-going growth sequenc consum partli off-set
normal season step microarray mainli dtc consum revenu ilmn
guid call rev rais prior guid
pictur massiv sequenc consum market think penetr
estim peopl ever sequenc wg develop
world popul billion estim ever
genotyp world develop popul estim
cancer patient babi rare diseas sequenc respect
cost whole genom sequenc wg drop
lower today expect within year see path
peopl sequenc wg within year driven pop
seq liquid biopsi oncolog children think
sequenc project given lead accuraci
throughput cost note we could add million
count consum genotyp to-dat envis year
consum market penetr view peopl genotyp
prior decad combin driven ancestri power
array indic earli total sampl
genotyp expect rise consum awar
robust sale demand gener sell amazon price discount
kit consum recent fda-approv market
expans track dtc compani ww uptak helix
growth china next year see path genotyp ww
end look test think ancestri could
reach similar level think china could reach within year
real updat estim call
billion sinc analyst day ad nipt carrier screen
rare undiagnos diseas babi consum genom
oncolog pop seq estim revis
least develop world alon cant help point
estim direct-to-consum genet test market
million three year one ilmn custom
segment gener revenu excess billion ancestri
ancestri sold approxim million genotyp test kit sinc incept
remind indic million genotyp test kit sold
greater last ten year demand combin also
indic million sampl ever genotyp sinc incept
roughli estim million ancestri million
think demand elast big wait get genom
base convers sever largest custom
indic good sens demand sequenc look like
cost sequenc drop increment
unfortun wouldnt quantifi inflect look like
surpris us includ system geising offer whole
exom sequenc member radi children demonstr util
screen babi genotyp stori uk
lead govern across world fund project sequenc
popul better understand genet translat better clinic
prevent healthcar think recent inflect part driven
countri want feel left behind out-innov countri
wegen someon els china may bigger eventu
earli help china-bas direct-to-consum genet test compani wegen
buy unchang target price june
biomed devic servic
establish lab wegen databas size
peopl sinc china popul larger us think
eventu achiev genotyp member know chines dtc
consum market infanc far earli call winner even
realist predict much accuraci larg market grow year
isnt real challeng continu invest innov
watch investor meet ilmn manag acknowledg oxford
nanopor made stride improv accuraci long-read
long path go improv overal accuraci cost throughput despit
differ similar stori true ion torrent thermo bgi
pacbio best guess year lead vs potenti
competitor like ahead pack far new product develop go
dont yet know invest year
roughli revenu advanc industry-lead innov new
product launch come believ futur innov may includ
drive cost whole genom sequenc like increment
time incorpor acquisit edico genom
offer help speed genom interpret incorpor long linked-
read sequenc capabl offer advanc speed sequenc
whole genom whole exom possibl genotyp among initi
pop seq liquid biopsi studi drive multi-year demand estim
peopl sequenc within next year popul sequenc
liquid biopsi studi estim sequenc pop seq
liquid biopsi studi cancer children think
sequenc project given lead accuraci throughput
cost note we could add million count
consum genotyp to-dat think could grow
year pop seq uk lead fast-follow includ us china franc
among project underway see figur liquid biopsi studi
estim sequenc grail alon within year
firmli believ best basic posit compani
benefit popul sequenc precis medicin project month
launch novaseq observ rise fund global govern
corpor sponsor popul sequenc project target number goal
demograph
sequenc estim compar less million peopl
world-wide sequenc today estim compar
launch hiseq januari clear us
obviou beneficiari massiv expect inflect genom
sequenc next year dont believ anoth
compani posit compet effect sequenc genom anytim soon
buy unchang target price june
biomed devic servic
major popul sequenc project
either get ground
make ground advanc bold goal
middl
us us research program announc januari launch spring
us research program offici launch may form
invest us nation institut nih fy
budget acceler biomed research provid clinician new tool
select therapi use individu approach patient
us origin precis medicin initi pmi announc former
presid barack obama januari name rebrand oct
goal collect genet health data million volunt
target complet date fund earmark year
us seek build scale scope enabl research wide rang
diseas common rare well improv understand healthi
state us look build statist power detect associ
environment and/or biolog exposur wide varieti health outcom
individu particip us program given complementari diagnost
provid blood urin spit sampl give physic measur
gain access electron medic record sampl undergo genotyp
whole genom sequenc bode extrem well ilmn sequenc
array busi view project enrol particip
april aim process sampl within year may
nation launch achiev goal us seek partner major
genom center process samples/year time program
director eric dishman set goal process sampl per year
us intend make avail fall genotyp wg data
first particip half data includ particip genotyp
half includ particip genotyp wg readout
us look build capac genet counsel believ would come
form partnership us manag eric dishman former vice-president
corpor health life scienc group serv director
pmi us research program mr dishman offer period video updat
attic believ certainli worth watch statu broader
nation roll-out program recruit site across unit state
buy unchang target price june
biomed devic servic
figur imagin diseas genotyp whole genom sequenc data assembl
one databas estim diseas estim found million american
nih precis medicin initi pmi work group report advisori committe director nih sep
uk genom england genom project initi
genom england separ compani wholli own uk depart
creat sequenc whole genom
servic nh patient genom england wholli own depart
 social fund came nation institut
research nh england public health england health educ england four
main aim creat ethic transpar program base consent
bring benefit patient set genom medicin servic nh
enabl new scientif discoveri medic insight kick start
develop uk genom industri
date genom sequenc octob
project expect complet end sequenc
done wellcom trust sanger institut near cambridg
genom project target patient certain rare diseas plu
famili cancer patient donat blood saliva tumor sampl
depend part project patient sampl sent uk
biocentr valid prep send sampl illumina cambridg
facil sampl sequenc digit file sent data center
may access commerci academ research
buy unchang target price june
biomed devic servic
genom england sequenc human genom patient
everi cancer patient contribut two genom comparison one healthi
cell one cancer three genom come everi rare diseas
particip comparison one affect person two close
blood rel assum half genom come cancer half
rare diseas genom england expect sequenc follow
diseas genom patient healthi rel
thu genom project sequenc approxim peopl
total present diseas healthi rel
genom project launch via prime minist england
detail project final part deal
servic whole genom sequenc secur deal worth
turn pledg invest around work
england year creat knowledg job sequenc genom england
extend initi sequenc partnership februari
announc bioinformat compon term partnership illumina
task develop interpret report tool deliv report
genom sequenc project
whole exom sequenc we sampl uk biobank end
regeneron genet center rgc establish one
top largest exom sequenc genom center world awar
certainli largest kind affili major drug compani regeneron
built comprehens genet databas pair sequenc exom de-
identifi electron health record peopl far regeneron
believ trove whole exom sequenc data enabl determin
larg scale genet factor caus influenc rang human diseas
januari regeneron announc consortium alnylam
pharmaceut astrazeneca sequenc exom
particip uk biobank five pharmaceut
compani agre invest consortium help creat genet
data consortium regeneron expect complet whole exom
sequenc sampl end per year
note remark ambiti plan expect initi alon help move
needl sequenc consum growth regeneron use
novaseq least one time employ sizeabl fleet high-throughput
outdon regeneron continu work geising
commiss mycod commun initi enrol
complet whole exom sequenc patient-particip alreadi
deliv medic relev result particip primari care doctor
geising mycod particip receiv clinic report
healthi nevada project initi septemb renew march
renown health desert research institut launch healthi nevada
project septemb goal project improv popul health
integr person healthcar environment data socioeconom
determin help nevada address complex environment health
problem pilot phase studi sep dec enrol
particip less hour subsequ dna sampl collect
buy unchang target price june
biomed devic servic
particip complet work day sampl underw dna
genotyp complet
renown health launch phase two enrol march target
addit particip undergo whole exom sequenc
consum genom spin helix healthi nevada project close open
enrol first studi particip five day move
demographic-bas elig remain test slot phase two
organ believ move exom sequenc invit addit
particip dramat acceler find human genom
improv prevent health
grail circul cell-fre genom atla studi ccga strive studi
grail enrol peopl population-scal clinic studi
ccga strive look complet enrol studi year grail
enrol goal ccga goal strive
expect grail sequenc hundr thousand genom accomplish
end mission earli launch grail launch two clinic trial circul
cell-fre genom atla studi ccga strive studi purpos
circul cell-fre genom atla studi ccga character landscap
cell-fre nucleic acid cfna profil individu without cancer
observ ccga studi enrol least peopl cancer
without cancer interrog biolog tumor biopsi tissu sampl
circul tumor-deriv nucleic acid blood grail collabor
collect clinic outcom enrol particip least year
purpos strive studi launch april train
valid test detect breast cancer train develop pan-canc test
detect multipl cancer earli stage strive multi-cent longitudin
prospect observ studi enrol women time
screen mammogram
grail releas data ccga studi mid-may present earli
find four abstract two oral present june
sensit analys conduct sequenc blood sampl
particip newli diagnos cancer three prototyp genom sequenc
assay data three assay present asco annual meet
detect rate sensit percent specif rang percent
percent earli stage stage i-iii cancer typic caus high
mortal includ colorect esophag head neck liver ovarian pancreat
triple-neg breast cancer well lymphoma multipl myeloma
buy unchang target price june
biomed devic servic
figur grail see earli success ovarian liver cancer detect though still work number lead cancer
strong biolog signal also detect lung cancer lead caus cancer
death global data highlight late-break abstract
featur asco press program saturday june abstract
cancer type exhibit low signal earli stage less percent
sensit includ prostat thyroid uterin renal cancer melanoma
pre-plan sub-studi ccga three prototyp genom sequenc assay
evalu potenti method blood-bas test earli cancer detect
first train phase sub-studi blood sampl particip
newli diagnos cancer yet receiv treatment particip
without diagnos cancer sequenc three prototyp assay twenti
differ cancer type across stage includ sub-studi
target sequenc pair cell-fre dna cfdna white blood cell
detect somat mutat singl nucleotid variant small
whole-genom sequenc pair cfdna white blood cell detect
somat copi number chang
whole-genom bisulfit sequenc cfdna detect abnorm cfdna
buy unchang target price june
biomed devic servic
guardant health guardant million announc
guardant million initi announc last year seek provid
infus data cancer research field goal acceler
develop blood-bas test earli cancer detect privately-held guardant
redwood citi ca commerci stage compani sell industry-
lead liquid biopsi test oncologist
year ago list price perform
time sinc launch set goal deploy test
peopl next year
mid-may receiv expedit access pathway eap
design us fda intend speed review breakthrough
technolog medic devic serv unmet medic need
program fda work guardant final data develop plan
provid access senior fda offici facilit collabor cross-
disciplinari review fda expect replac eap soon new
breakthrough devic program pre-market approv applic eap-design
devic typic receiv prioriti review fda submiss design
breakthrough devic set receiv prioriti review
guardant look obtain first fda-approv comprehens liquid biopsi panel
guardant intend submit fda later to-dat believ guardant
data stood apart extens valid support
clinic outcom studi
geising look sequenc healthi patient announc may
pennsylvania-bas health system geising announc earli may plan
includ dna sequenc routin clinic care patient goal
initi promot anticipatori health care instead respons sick care
latter compris major healthcar visit recal geising enrol
particip mycod commun initi use
regeneron genet center sequenc patient exom select genom
geising clinic dna sequenc effort launch pilot
program within next six month clinic dna program spread
throughout geising expans geograph footprint across pennsylvania
southern new jersey geising serv million resid throughout
counti central south-centr northeast pa southern nj
million veteran program mvp mvp lot room expand
look shift genotyp affymetrix exom whole genom seq
million veteran program mvp larg partnership us depart
veteran affair va veteran us arm forc goal mvp
better understand gene affect health ill improv health care
veteran mvp seek establish one largest databas genet militari
exposur lifestyl health inform research find base mvp may lead
new way prevent treat ill veteran find may help
answer question like treatment work well veteran
other veteran greater risk develop ill
prevent certain ill first place expect
enrol million veteran next year mvp aim one
largest databas kind unit state
feb heard dr john michael gaziano md mph harvard medic
school us dept veteran affair cooper studi program veteran
epidemiolog research inform center maver indic mvp
buy unchang target price june
biomed devic servic
genotyp veteran date use affymetrix array
look enrol million veteran million time
expect move whole genom sequenc vast major
expect wg plu we plu
januari heard sumitra muralidhar veteran affair ad
genotyp veteran african american hispan
male data bracket
mvp plan enrol beneficiari dept defens dod futur
area focu mvp program includ post-traumat stress disord
ptsd suicid prevent veteran commit suicid everi day project
surround prostat cancer cardiovascular risk
mvp project on-going research involv
chronic kidney diseas ckd metabolom new area like
phenom proteogenom
kaiser permanent research bank april seek add bank
kaiser permanent enrol goal enrol peopl
larg biobank initi impli theyv enrol member
patient recruit kp research bank april kaiser goal collect
dna sampl blood patient respons behavior environment
factor member kp enrol member
seek add anoth learn kaiser updat nazneen
execut director kaiser permanent research bank februari
attend precis medicin world confer mountain view ca
perkinelm take aim newborn undiagnos diseas august
announc august launch genet clinic
genom servic lab india china offer
global genom lab test platform perform screen diagnost test
special newborn screen high throughput next gener sequenc
rare inherit diseas perkinelm genet two state-of-the-art clia-certifi
clinic laboratori base pittsburgh pa branford ct process
biochem profil tier molecular confirmatori test sanger ngs-base
panel exom genom sequenc order novaseq
septemb instal instrument
perkinelm whole exom sequenc whole genom sequenc servic
offer combin biochem profil target rapid we wg
genet diseas diagnosi genom servic initi focu newborn
viacord custom though perkinelm genet also develop biochem
molecular test menu explor segment pharmaceut
compani market serv china india
buy unchang target price june
biomed devic servic
sept announc collabor in-depth genom idg
support idg whole genom sequenc wg diagnost program bring
genet diagnosi patient across wide rang neurolog condit includ
rare/orphan disord collabor help pave pathway toward
improv diagnos treatment overse collabor
dr madhuri hegd vice-president cso perkinelm laboratori servic dr hegd
team activ engag work group acmg defin
nation standard clinic genom
idg offer program physician fund initi
cost patient program plan sequenc genom patient
suffer rare undiagnos genet diseas rugd program
leverag larg network neurologist idg leadership previous work
screen approxim patient gene panel idg activ
seek pharmaceut biotech partner share vision transform
landscap diagnos therapi
genet provid clinic wg interpret servic diagnost
report gener idg idg use de-identifi genom clinic data
support hundr rare neurolog condit
april announc launch test consum
genom spin-out helix test focu gene identifi american
colleg medic genet genom acmg highli penetr
 evalu clinic util wg infant nicuseq trial
nicuseq prospect trial evalu clinic util human whole genom
sequenc wg compar standard acut neonat infant
summari prospect multi-sit studi evalu clinic util clinic whole
genom sequenc cwg one group receiv cwg clinic report
day blood sampl receiv group continu receiv
standard care day standard care group receiv cwg
clinic report day part secondari tertiari analys group
follow total day blood sampl enrol proband
collect ship illumina clinic servic laboratori icsl icsl
conduct cwg test trugenom undiagnos diseas test trugenom
test trugenom test cwg result provid princip investig
pi designe evalu proband test outcom base aggreg
medic inform inform cwg soc result
sequenc cwg either day day acut ill newborn popul
mask descript investig mask studi arm day
ensur soc throughout first day studi
small hudsonalpha institut base huntsvil
alabama plan sequenc genom newborn neonat nurseri
birth defect sign genet disord four-year million
grant nih sequenc initi fall within nih sponsor clinic
buy unchang target price june
biomed devic servic
sequenc evidence-gener research consortium aim learn
implement genom sequenc clinic care specif
medic underserv popul evalu impact health outcom
first iter program involv whole genom sequenc children
parent unexplain genet disord found diagnos
key take-away number commerci academ
government organ priorit person medicin research host
applic enabl see traction build
new countri organ announc uniqu precis medicin studi
china year initi octob
specif clear yet expert believ chines initi
larger scope budget us pmi one clue china earmark
billion rmb billion usd spread year popul significantli
larger us effort consist hundr separ project
sequenc genom gather clinic data
sichuan univers west china hospit announc sequenc million human
genom equal goal entir us initi
singapor genomeasia initi februari
singapor nanyang technolog univers ntu host databas
project announc non-profit multi-national consortium
genomeasia februari project aim cover least countri
across asia major ethnic group contin week project
launch professor stephean schuster announc organ
biobank sampl individu consent broad genom
research test sequenc genom
franc franc medecin genomiqu initi june
plan invest build network sequenc analysi center
capabl process genom per year overal report lay
three object first year program first object make
franc leader among countri alreadi lay groundwork genom
medicin second prepar integr genom medicin
normal cours patient care countri mean sequenc
genom per year third goal establish nation genom
medicin industri serv sourc innov econom growth
ireland genom medicin ireland limit wuxi nextcod partnership
announc januari
life-sci start-up genom medicin ireland limit gmi wuxi
nextcod januari announc launch long-term strateg allianc
conduct popul genom research ireland aim advanc discoveri
develop novel therapeut approach rang seriou diseas
collabor focu major chronic diseas within oncolog
buy unchang target price june
biomed devic servic
neurosci immunolog affect hundr thousand peopl ireland
hundr million world-wide financi term disclos
collabor result sequenc genom
volunt particip across ireland seek novel insight biolog
process underli complex diseas use research databas
develop gmi identifi new molecular approach therapeut drug discoveri
develop well develop companion diagnost
saudi arabia saudi genom project shgp announc
sound fund dedic resourc nation determin shgp
target sequenc human genom next five year
conduct world-class genomics-bas biomed research saudi
popul saudi arabia high burden genet diseas mostli due
high rate marriag rel around marriag unclear us
mani genom sequenc date
mexico slim initi genom medicin america sigma sigma ii
carlo slim foundat broad institut came togeth launch
carlo slim center health research broad institut
one major research focu sigma type diabet one
common diseas mexico incid higher global rate sigma
project set identifi genet risk factor contribut dispar
translat find improv method diabet treatment prevent
first phase project sigma scientist sequenc character
tissu sampl mexican mexican american
unpreced analysi led discoveri first identifi common genet
variant shown predispos latin american popul diseas
carlo slim foundat donat total million toward sigma creat
develop genom medicin benefit latin america world
foundat institut said sigma continu earlier discoveri effort
goal develop diagnost tool breast cancer diabet complet
genet analysi diseas creat therapeut roadmap guid
develop new treatment launch full-scal effort target medullari
cystic kidney diseas type first draft genome-wid cancer
depend map releas juli
estonia estonian biobank estonian genom centr univers tartu
egcut initi
last year estonia work dilig collect analyz
popul genom data modern e-health system alreadi cover entir
popul estonian genom center institut univers tartu
biobank cover approxim health data genet sampl
estonia citizen estim genom sequenc date
near futur center intend scan genom half popul half
million peopl new pilot program person medicin
center combin collect data profil expect
new person health servic estonian citizen get advic better
care help live longer healthier live
buy unchang target price june
biomed devic servic
ilmn recent result solid see
room robust growth ahead
deliv top-lin beat rais fy guid mainli reflect
beat guid street driven broad spatter growth across
busi result led y/i growth sequenc consum
record microarray servic y/i q/q mainli ancestri com
posit read-through small cap buy-rat bull thesi squar intact
continu call must stock particularli large-cap growth
mandat remain top pick given domin leadership
nascent next-gen sequenc market plethora growth driver ahead
beat driven array consum rev y/i
beat our/street beat beat arrays/servic
y/i beat consum y/i vs model driven
robust novaseq nextseq pull-through thank sequenc wg we
liquid biopsi adj ep crush
driven revenu beat benefit fx benefit one-tim
tax benefit relat recogn loss helix adj gm y/i
beat adj om beat
guid ilmn call compani guid rev modestli
q/q ahead prior expect
on-going growth sequenc consum partli off-set normal season
step microarray mainli dtc consum revenu
rais guid suggest visibl growth appear leav room anoth
rais year call rais revenue guid
y/i guid adj ep
vs prior given beat guid
guid street rais guid suggest
higher revenu view small readili achiev given
manag expect grow consum microarray
holi array gener total services/oth rev
y/i beat array services/oth grew q/q
record primarili due process ancestri com sampl order
holiday season microarray consum also record y/i
q/q primarili direct-to-consum industri leader dtc
custom agrigenom illumina ceo franci desouza indic
compani track direct-to-consum compani global
novaseq call indic see strong util
novaseq flow cell expect novaseq shipment declin q/q
longer provid quarterli novaseq instrument number howev see
strong feedback new flow cell launch feb reiter
seq placement guid unit y/i order came
custom new sequenc bench-top system
move clinic applic includ immuno-oncolog recent
announc import new partnership bristol-my squibb bm measur
biomark includ tumor mutat burden tmb seek predict whether
patient respond immunotherapi checkpoint inhibitor intend
develop commerci distribut ivd support bmss oncolog
immunotherapi addit announc mid-april partnership develop
buy unchang target price june
biomed devic servic
commerci multi-gen panel broad tumor profil result
distribut ngs-base companion diagnost pan-canc indic co-
develop partnership seek approv version trusight
tumor companion diagnost loxo oncolog larotrectinib target
ntrk gene fusion target ret gene alter across tumor
type announc consist object play leadership
role enabl sequenc oncolog applic support routin test
immuno-oncolog therapi select monitor
research novaseq convers schedul may
good thing durat growth novaseq adopt like continu
good pace least like longer view
illumina hiseqx custom instal least one novaseq
fulli convert fleet instrument novaseq manag cite
rational cadenc clinic translat research activ end
result novaseq like multi-year adopt cycl least
like end longer view depend whether
follow anoth blockbust launch perhap
new custom novaseq call
state novaseq order either new sequenc
previous benchtop custom new-to-illumina custom academ
translat lab clinic test whole exom sequenc we
whole genom sequenc wg convert desktop-onli we
wg circul tumor dna liquid biopsi work methyl analysi rna
clinic non-invas prenat test nipt also continu grow
work harvard pilgrim show data highlight util averag risk nipt
test may facilit broader commerci payor averag risk nipt
view clear grow adopt average-risk nipt mark materi growth
driver next sever year whenev aet decid cover
average-risk women make birth year us
buy unchang target price june
biomed devic servic
figur popul sequenc liquid biopsi project like drive sequenc consum util year come
canaccord genuiti partial list project
buy unchang target price june
biomed devic servic
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
buy unchang target price june
biomed devic servic
buy unchang target price june
biomed devic servic
figur detail revenu part revenu instrument famili
buy unchang target price june
biomed devic servic
figur detail revenu part revenu instrument famili
buy unchang target price june
biomed devic servic
